select a format

Single User License
USD 2000 INR 128080
Site License
USD 4000 INR 256160
Corporate User License
USD 6000 INR 384240

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H2 2015

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7037IDB
  • |
  • Pages: 31
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H2 2015', provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6

Therapeutics Development 7

Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Overview 7

Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis 8

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics under Development by Companies 9

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Products under Development by Companies 12

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Companies Involved in Therapeutics Development 13

Human Stem Cells Institute 13

Lacer, S.A. 14

Nuo Therapeutics, Inc. 15

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

ALD-201-Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders-Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

LA-419-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Protein for Cardiovascular Diseases-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Recent Pipeline Updates 28

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects 29

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Tables

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 7

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Human Stem Cells Institute, H2 2015 13

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lacer, S.A., H2 2015 14

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Nuo Therapeutics, Inc., H2 2015 15

Assessment by Monotherapy Products, H2 2015 16

Number of Products by Stage and Target, H2 2015 17

Number of Products by Stage and Mechanism of Action, H2 2015 18

Number of Products by Stage and Route of Administration, H2 2015 20

Number of Products by Stage and Molecule Type, H2 2015 22

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics-Recent Pipeline Updates, H2 2015 28

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects, H2 2015 29

List of Figures

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 7

Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Assessment by Monotherapy Products, H2 2015 16

Number of Products by Top 10 Routes of Administration, H2 2015 19

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 19

Number of Products by Top 10 Molecule Types, H2 2015 21

Number of Products by Stage and Top 10 Molecule Types, H2 2015 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Human Stem Cells Institute

Lacer, S.A.

Nuo Therapeutics, Inc.

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutic Products under Development, Key Players in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Overview, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com